Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease. – International application and registration of patents on therapeutic use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.

Bukwang said it registered patents on the use and composition of ‘JM-010’ with Korean Intellectual Property Office (Title : Combinations of serotonin receptor agonists for treatment of movement disorders). ‘JM-010’ is a treatment for ‘Levodopa-induced dyskinesia in Parkinson’s disease’ developed by Bukwang’s subsidiary named Contera Pharma ApS, which is a Danish bio venture specialized in […]

Bukwang Pharmaceutical Co., Ltd. LID treatment ‘JM-010’ is approved for Orphan Drug Designation

Bukwang recently announced that Ministry of Food and Drug Safety (MFDS) has granted JM-010 for the treatment of levodopa-induced dyskinesia (LID). JM-010 is currently being developed by a CNS specialized bioventure Contera Pharma, a subsidiary of Bukwang. LID is a movement disorder occurs inevitably in 60~70% of Parkinson’s disease patients who receive long-term levodopa treatment. […]

Press release, JM-010CS01, Phase IIa/cPoC study

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has successfully been dosed to cohorts of patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia in a Phase IIa/Proof-of-Concept study. The primary study objectives concerning efficacy and safety were fulfilled. The aim is […]

US patent covering JM-010 for treatment of movement disorders has been granted

Bukwang Pharm and its fully owned subsidiary Contera Pharma are pleased to announce that the United State patent covering the investigational medical product, JM-010 and analogues thereof has been granted. Dr. Hee-Won Yoo, President and co-CEO of Bukwang Pharm stated: “The US patent is a significant milestone for Bukwang Pharm and supports the further development […]

Press release, JM-010CS01, Phase IIa/cPoC study

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has been dosed to the first patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia. The Phase IIa/Proof-of-Concept study is a randomized, double-blind, placebo-controlled, 2-way crossover study, which will assess the efficacy, safety/tolerability and […]

Solural Pharma and Contera Pharma initiate Eurostar sponsored project in Parkinson’s disease

Solural Pharma and Contera Pharma have in collaboration with Ernst Moritz Arndt University Greifswald, Germany and Erweka GmbH, Germany been awarded a Eurostar grant to support a project to develop new treatments of morning akinesia associated with Parkinson’s disease (PD). Parkinson’s disease, which affects 1 in 100 people over the age of 60, is primarily […]